Activaero appoints Christian Pangratz
pharmafile | June 27, 2011 | Appointment | Sales and Marketing | appointment, sales and marketing
Activaero GmbH has appointed Christian Pangratz as chief business officer, with a brief to lead its business development, marketing and alliance management activities.
He joins the German controlled breathing inhalation technology and therapeutics company from San Francisco-based Nektar Therapeutics, where he was executive director of business development.
Gerhard Scheuch, founder and chief executive of Activaero, said: “The creation of a new full-time business development position is the consequence of the excellent progress of our clinical development programs and our recent organisational growth.
“We welcome Mr Pangratz to our leadership team and we are convinced that his expertise will bring a strong new perspective to our commercial efforts.”
Christian Pangratz will replace Dr Henrik Luessen as chief business officer, who has decided to re-focus on his own consultancy firm Tytonis, but will continue to support Activaero’s business development team on a part time basis.
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






